Haematologic Neoplasms
1 clinical trials · Condition
◉ Watch Haematologic Neoplasms
| Record | Firm | Date |
|---|---|---|
| A Study of AZD2962, an IRAK4 Inhibitor (IRAK4 [a Body Protein] Blocker), in Participants With Haematologic Neoplasms (Blood Cancers) (NCT07064122) | AstraZeneca | 2025-11-03 |
Track Haematologic Neoplasms automatically
Every clearance here is in the API, with alerts when new ones post.